Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KINNATE BIOPHARMA INC.

(KNTE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
19.12(c) 19.51(c) 19.98(c) 18.74(c) 19.77(c) Last
69 713 96 900 88 818 145 627 53 470 Volume
-6.60% +2.04% +2.41% -6.21% +5.50% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -89,3 M - -
Net cash position 2021 233 M - -
P/E ratio 2021 -9,65x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -114 M - -
Net cash position 2022 234 M - -
P/E ratio 2022 -8,00x
Yield 2022 -
Capitalization 864 M 864 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 61
Free-Float 85,0%
More Financials
Company
Kinnate Biopharma Inc. is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The Company utilizes its deep specialization in structure-based drug discovery, translational research and patient-driven precision medicine, which is collectively referred as Kinnate Discovery Engine, to develop its targeted therapies. 
More about the company
Ratings of Kinnate Biopharma Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about KINNATE BIOPHARMA INC.
11/11Wedbush Lifts Kinnate Biopharma's Price Target to $53 From $50, Keeps Outperform Rating
MT
11/10Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/10KINNATE BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/10Kinnate Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/10Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results
AQ
11/08Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
AQ
11/01Kinnate Guardant Molecular Landscape Study
PU
11/01Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings..
AQ
10/29Kinnate Biopharma's Chief Scientific Officer to Step Down
MT
10/28Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer - Form 8-K
PU
10/28KINNATE BIOPHARMA INC. : Change in Directors or Principal Officers, Other Events, Financia..
AQ
10/28Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer
AQ
10/28Kinnate Biopharma Inc. Announces Stepdown of Eric Murphy as Chief Scientific Officer, E..
CI
10/07KINNATE BIOPHARMA INC : . Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase In..
AQ
10/07Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase In..
CI
More news
News in other languages on KINNATE BIOPHARMA INC.
10/29Le directeur scientifique de Kinnate Biopharma quitte ses fonctions
More news
Analyst Recommendations on KINNATE BIOPHARMA INC.
More recommendations
Chart KINNATE BIOPHARMA INC.
Duration : Period :
Kinnate Biopharma Inc. Technical Analysis Chart | KNTE | US49705R1059 | MarketScreener
Technical analysis trends KINNATE BIOPHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 19,77 $
Average target price 47,50 $
Spread / Average Target 140%
EPS Revisions
Managers and Directors
Nima M. Farzan President, Chief Executive Officer & Director
Neha Krishnamohan Chief Financial Officer & Executive Vice President
Dean Jonathan Mitchell Chairman
Eric A. Murphy Chief Scientific Officer
Richard Williams Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
KINNATE BIOPHARMA INC.-50.30%864
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-40.67%24 745